Stockreport

Denecimig (Mim8) significantly reduced annualized bleeding rate in people with hemophilia A, regardless of inhibitor status, in phase 3 data published in NEJM [Yahoo! Finance]

Novo Nordisk A/S  (NVO) 
Last novo nordisk a/s earnings: 2/5 01:31 am Check Earnings Report
US:NYSE Investor Relations: novonordisk.com/investors.html
PDF prophylaxis and on-demand treatment in people with hemophilia A, with or without inhibitors The study evaluated the efficacy and safety of dosing denecimig in adults a [Read more]